Best Genomics Companies in Victoria, Australia
The 33 best Genomics companies in Victoria, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Telix Pharma.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Victoria
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Telix Pharma Developer of theranostic radiopharmaceuticals for imaging and treating cancer | $25M | 72 mo ago | Public | — | 2015 | DrupalApple iCloud MailPHP+28 | — | — |
| 2 | Antisense Therapeutics Developer of RNA-based antisense drugs | $10M | 71 mo ago | Public | — | 2001 | — | 123 patents Antisense oligonucleotide therapeutics for neurodegenerative and muscular disease treatment | — |
| 3 | INOVIQ Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer | $6M | 12 mo ago | Public | Leearne Hinch CEO | 1983 | Cart FunctionalityZURB FoundationMicrosoft ASP.NET+20 | 4 patents Polymer resin formulations and extracellular vesicle-based diagnostic/therapeutic technologies | — |
| 4 | Rhythm Biosciences Developer diagnostic tests for the detection of cancer | $3M | 28 mo ago | Public | David Atkins Chief Executive Officer | 2016 | WordPressMySQLPHP+21 | — | — |
| 5 | Mass Dynamics Provider of platform for proteomics and discovery scientists | $2M | 65 mo ago | Seed | Aaron Triantafyllidis Co-Founder | 2015 | — | — | — |
| 6 | Zip Diagnostics Developer of molecular diagnostic tests and instruments for infectious diseases | $750K | 66 mo ago | Funding Raised | Jack Richards Co-Founder | 2019 | Wix eCommerceCart FunctionalityWix+20 | 7 patents Rapid lateral‑flow immunoassay devices for point‑of‑care biological and environmental testing | — |
| 7 | Eugene Labs Provider of genetic-based health care services | $525K | 69 mo ago | Series A | Zoe Milgrom Co-Founder & Director | 2016 | Cart FunctionalityShopifyTailwind CSS+27 | — | — |
| 8 | Allele Microbiome Provides DNA based microbiol screening test of gut, oral, soil and food samples | — | — | Deadpooled | Kriben Govender Co-Founder & MD | 2017 | — | — | — |
Top 7 Genomics companies in Victoria
#1
Public · Notting Hill, Victoria · founded 1983 · 5 employees$6.1Mraised▾
Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer. The company has an hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes.
- Oct 2025Post IPO$6.1M
#2
Public · Melbourne, Victoria · founded 2016$2.7Mraised▾
Developer diagnostic tests for the detection of cancer. The company has developed a minimally invasive blood test for one of the most common forms of cancer. The flagship product is ColoSTAT to detect colorectal cancer.
- Jun 2024Post IPO$2.7M
#3
Public · Melbourne, Victoria · founded 2015 · 234 employees$25Mraised▾
Developer of theranostic radiopharmaceuticals for imaging and treating cancer. It offers TX250, a Girentuximab antibody with an imaging payload (124-I or 177-Lu), targeting carbonic anhydrase IX, indicated for CCRC, and treatment with 177Lu and NSCLC.
- Nov 2020Post IPO$25M
#4
Public · Toorak, Victoria · founded 2001 · 8 employees$10.1Mraised▾
Developer of RNA-based antisense drugs. The company develops targeted RNA-based antisense drugs. It has four products in its pipeline. Its two lead candidates are in phase III clinical trials for acromegaly and multiple sclerosis. In addition, it has two additional candidates that are in preclinical testing for prostate cancer and asthma.
- Nov 2020Post IPO$7.3M
- Apr 2018Post IPO$581.6K
- Apr 2008Post IPO$2.2M
#5
Seed · Melbourne, Victoria · founded 2015 · 16 employees$1.5Mraised▾
Mass Dynamics provides mass spectrometry software for proteomics and discovery scientists. MD Discovery creates insights into disease mechanisms, discovers new drugs, or identifies changes in protein levels from a set of designed experiments. MD Targeted is a service made to allows drug products to be characterized.
- May 2021Seed$1.5M
#6
Funding Raised · Collingwood, Victoria · founded 2019$750Kraised▾
Developer of molecular diagnostic tests and instruments for infectious diseases. The company is developing a sensitivity molecular test system for SARS-CoV-2 and sexually transmitted diseases.
- Apr 2021Grant (prize money)$750K
#7
Series A · Richmond, Victoria · founded 2016 · 31 employees$525Kraised▾
Provider of genetic-based health care services. It provides a saliva-based home kit and the result is obtained on the mobile app. It provides the test for planning a healthy pregnancy, to find out the carrier of any disease like Cystic Fibrosis, Spinal Muscular Atrophy, Thalassemia, Tay-Sachs disease, and proper healthcare.
- Jan 2021Series A$3.5M
- Feb 2019Angel$525K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Victoria is moving
A read on the academic research around Bioinformatics in Victoria — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 42 papers.
- University of Victoria14
- Victoria University of Wellington4
- Bahawal Victoria Hospital4
- Victorian Comprehensive Cancer Centre3
- The Royal Victorian Eye & Ear Hospital3
- GenBank2
- Environmental DNA2
- Mitochondrial DNA2
- Biodiversity2
- Taxon2
- Context (archaeology)2
- Proteomics2
- Biomarker2
- Population2
- Breast cancer2
- Population2
- Identification (biology)2
- Saxitoxin1
- Dinoflagellate1
- Algal bloom1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.